artemether-lumefantrine (AL) is one of 73 small molecule programs targeting Plasmodium falciparum malaria. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
94 competitors in Malaria
Dihydroartemisinin-Piperaquine
Rabies Vaccine
YF-Vax
Krintafel
artemether-lumefantrine (AL)
Artesunate-Amodiaquine
Pfspz Challenge
R21/matrix-M
Pyramax
Hexavalent Vaccine
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources